Bullman, Susan
Eggermont, Alexander
Johnston, Christopher D.
Zitvogel, Laurence
Article History
First Online: 21 December 2021
Competing interests
: S.B. has consulted for GlaxoSmithKline and BiomX; and is on the cancer program–scientific advisory board for BiomX. A.E. has received honoraria from Agenus, Biocad, BMS, BioInvent, CatalYm, CyteImmune, Dash Therapeutics, Ellipses, GlaxoSmithKline, IO Biotech, ISA Pharmaceuticals, Merck/Merck Sharp & Dohme, Nektar, Novartis, Pfizer, Sairopa, SkylineDx, Sellas, TigaTx and TTxDiscovery; and has stock options with CytImmune, Dash Therapeutics, IO Biotech, Sairopa, SkylineDx and Theranovir. C.D.J has consulted for Seres Therapeutics and Azitra. L.Z. is the founder of EverImmune, a biotechnology company involved in the cancer/microbiome space; is a member of the board of directors of Transgene and a member of the scientific advisory boards of Transgene and Sanofi; has research contracts with Daichi Sankyo, TRex, 9 Meters Biopharma and EverImmune; has received honoraria from Transgene; and is an employee of: Gustave Roussy and Faculté de Médecine Paris XI.